[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612738":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":34,"responsibleParty":52,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":11,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":11,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Weill Medical College of Cornell University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Drug","EXPERIMENTAL",null,[13],"Drug: Tirzepatide",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Tirzepatide","Participants will take tirzepatide weekly for 24 weeks. The dose will be adjusted on a monthly basis as clinically indicated.",[9],[21],{"name":22,"affiliation":5,"role":23},"Sarah Schmitz, MD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Lynelle Weis","CONTACT","646-962-2423","ljw4002@med.cornell.edu",{"name":31,"role":27,"phone":32,"phoneExt":11,"email":33},"Henry Cheng","646-962-6026","hec4011@med.cornell.edu",[35],{"facility":36,"status":37,"city":38,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Weill Cornell Medicine","RECRUITING","New York","10021","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-74.00597,40.71427,{"lat":46,"lon":45},[49],{"name":22,"role":27,"phone":50,"phoneExt":11,"email":51},"646-962-2111","hls9007@med.cornell.edu",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[55],{"name":56,"class":57},"National Center for Advancing Translational Sciences (NCATS)","NIH","100612738","phase-4-tirzepatides-role-in-postmenopausal-hr-breast-cancer-survivors-100612738",false,"NCT07257484","Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors","Inclusion Criteria:\n\n* Biologically female\n* Age ≥ 18\n* Obesity as defined by current BMI ≥ 30 kg\u002Fm²\n* Postmenopausal as defined by one or more of the following\n\n  * Age ≥60 years\n  * Age \\\u003C60 years with amenorrhea for ≥ 1 year\n  * Documented bilateral surgical oophorectomy\n  * Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrolment, and plan to remain on LHRH agonists throughout the trial\n* HR+ (ER and\u002For PR) stage 0-III breast cancer\n* Completed curative treatment (surgery, chemotherapy, radiotherapy) at least 12 weeks prior to enrolment\n* Insurance approval for tirzepatide or willing to pay out of pocket\n* Willing to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Stage IV breast cancer\n* Concomitant use of CDK inhibitors\n* Concomitant use of antiHER2 therapy\n* The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications\n* Other active malignancy requiring treatment\n* Enrollment in another investigational clinical trial\n* Contraindication to tirzepatide\n* Treatment with a GLP-1 receptor agonist within the last 3 months\n* Diabetes requiring insulin\n* Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol","FEMALE","18 Years",{"count":67,"type":68},30,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.",[74,75],"Obesity (Disorder)","Breast Cancer",[77,78,79,80],"tirzepatide","hormone receptor positive","HR+","postmenopausal","2026-06-10",{"date":83,"type":84},"2026-06-12","ACTUAL",{"date":86,"type":84},"2026-06-08",{"date":88,"type":68},"2028-02-25",{"name":5,"class":6},1]